



2009-12-09

PRESS RELEASE

Oasmia initiates clinical studies with the new pharmaceutical candidate Doxophos® Vet for treatment of cancer in dogs.

Oasmia Pharmaceutical AB announces today that the company's pharmaceutical candidate Doxophos Vet is entering clinical studies after showing promising results in preclinical studies. The clinical program is planned to start in the beginning of 2010 and will be carried out in the EU and the USA.

Doxophos Vet, developed by Oasmia, is a unique nanoparticle formulation of the substance doxorubicin (Adriamycin®). Doxorubicin is used today for treatment of breast cancer, lymphoma and lung cancer within human medicine. Treatment with doxorubicin entails a significant risk of untreatable and in some cases lethal heart diseases, especially the heart muscle disease cardiomyopathy, both in humans and animals.

- Results from preclinical studies with Doxophos Vet have shown a reduced cardiotoxic effect compared to treatment with other pharmaceuticals containing a corresponding dose doxorubicin, says Julian Aleksov, CEO of Oasmia.

As a result of a more dose intense treatment, Doxophos Vet is likely to have an increased effect compared to regular doxorubicin. A formulation which can be given in a higher dose with fewer side effects is in high demand on the veterinary market.

There are today 140 million dogs in the USA, EU and Japan and it is estimated that about 40 – 50 % of all dogs above eight years of age will have cancer. It is estimated that there are about 300 000 – 500 000 treatable dogs annually in the USA alone.

About Oasmia

Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favorable safety profile and better efficacy. The company name was registered in 1999 and is based in Uppsala, Sweden.

This press release may not be published or distributed, directly or indirectly, in or to the United States of America, Canada, Japan, Australia, New Zealand, or any other country where such action is wholly or partially subject to legal restrictions. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions. This press release does not contain or constitute an invitation or an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Oasmia Pharmaceutical AB (publ) ("Oasmia").

For more information, please contact: Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB.
E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at www.ngm.se and www.oasmia.com